Evaluation of OxxyneaGS in Acute Glycemic Regulation on Light Hyperglycemic Subjects
NCT04914416 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2022-08-10
Summary
This study aims to evaluate and select the best combination of polyphenol and white kidney bean ingredients in the acute glycemic modulation after a complete meal by measuring blood glucose and insulin.
Conditions
- Hyperglycemia, Postprandial
Interventions
- DIETARY_SUPPLEMENT
-
Verum T1
Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
- DIETARY_SUPPLEMENT
-
Verum T2
Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
- DIETARY_SUPPLEMENT
-
Verum T3
Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
- DIETARY_SUPPLEMENT
-
Verum T4
Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
- DIETARY_SUPPLEMENT
-
Verum T5
Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
- DIETARY_SUPPLEMENT
-
Verum T6
Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
- DIETARY_SUPPLEMENT
-
Verum T7
Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
- DIETARY_SUPPLEMENT
-
Verum T8
Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
- DIETARY_SUPPLEMENT
-
Verum T9
Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
- DIETARY_SUPPLEMENT
-
Verum T10
Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
- DIETARY_SUPPLEMENT
-
Verum T11
Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
- DIETARY_SUPPLEMENT
-
Verum T12
Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
- DIETARY_SUPPLEMENT
-
Verum T13
Verum T13 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
- DIETARY_SUPPLEMENT
-
Verum T14
Verum T14 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 900 mg in 3 capsules.
- DIETARY_SUPPLEMENT
-
Verum T15
Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
- DIETARY_SUPPLEMENT
-
Verum T16
Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.
- DIETARY_SUPPLEMENT
-
Verum T17
Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
Sponsors & Collaborators
-
Fytexia
lead INDUSTRY
Principal Investigators
-
Pedro Alcaraz Ramon · UCAM
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 20 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-06-15
- Primary Completion
- 2022-04-30
- Completion
- 2022-05-30
Countries
- Spain
Study Locations
More Related Trials
-
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
NCT04466566 ·Status: COMPLETED ·Phase: PHASE3
-
Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention
NCT00934336 ·Status: COMPLETED ·Phase: NA
-
Glucotoxicity and Acute Exercise
NCT01771614 ·Status: WITHDRAWN ·Phase: NA
-
The Glucagonotropic Effect of Amino Acids in Humans
NCT05954923 ·Status: COMPLETED ·Phase: NA
-
The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients
NCT00437918 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of Bethanechol on Glucose Homeostasis
NCT01434901 ·Status: COMPLETED ·Phase: PHASE1
-
Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176760 ·Status: UNKNOWN ·Phase: NA
-
Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia
NCT02685852 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
NCT07117240 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Intraoperative Dexamethasone and Its Effect on Hyperglycemia
NCT03646916 ·Status: WITHDRAWN ·Phase: PHASE4
-
GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients.
NCT04105608 ·Status: COMPLETED ·Phase: NA
-
The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.
NCT06498063 ·Status: RECRUITING ·Phase: NA
-
Incretin Regulation of Insulin Secretion in Monogenic Diabetes
NCT01795144 ·Status: COMPLETED ·Phase: PHASE1
-
The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D
NCT03246451 ·Status: COMPLETED ·Phase: NA
-
Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes
NCT01435980 ·Status: UNKNOWN ·Phase: PHASE4
-
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
NCT02793154 ·Status: TERMINATED ·Phase: PHASE4
-
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion
NCT04459338 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)
NCT05139316 ·Status: COMPLETED ·Phase: PHASE3
-
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
NCT06725693 ·Status: RECRUITING
-
Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia
NCT02996812 ·Status: COMPLETED ·Phase: PHASE1
-
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
NCT04135287 ·Status: UNKNOWN ·Phase: PHASE4
-
Carnitine Levels and Carnitine Supplementation in Type I Diabetes
NCT00351234 ·Status: COMPLETED
-
Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.
NCT02109315 ·Status: WITHDRAWN ·Phase: PHASE1
-
GLP-1 REceptor Agonists and Real World EvIdeNce
NCT03959865 ·Status: UNKNOWN
-
Effect of Vagus Stimulation on Peripheral Glucose Metabolism
NCT03615209 ·Status: COMPLETED ·Phase: NA